10-K: Acadia Healthcare Reports $1.1B Loss Amid Impairment Charges

Acadia Healthcare Company, Inc. reported a significant net loss of $1.1 billion for fiscal year 2025, primarily driven by substantial goodwill impairment charges and increased legal settlement expenses, despite revenue growth.

Summary

• Acadia Healthcare Company, Inc. reported a net loss attributable to Acadia Healthcare Company, Inc. of $1,102.8 million for the year ended December 31, 2025, a significant decline from a net income of $255.6 million in 2024.
• Revenue increased by 5.0% to $3,312.8 million in 2025 from $3,154.0 million in 2024, with same facility revenue growing 4.9%.
• The company incurred a non-cash goodwill impairment charge of $996.2 million in 2025, primarily due to higher professional and general liability (PLGL) expenses, lower future revenue projections related to Medicaid reimbursement changes, and a sustained decline in stock price.
• Legal settlements expense surged to $151.0 million in 2025, including $147.5 million for the 2019 Securities Litigation and $3.5 million for the Desert Hills Litigation.
• Total debt (net of debt issuance costs, discounts, and premiums) stood at approximately $2.5 billion as of December 31, 2025.
• The company refinanced its Prior Credit Facility on February 28, 2025, with a new Credit Facility providing a $1.0 billion revolving credit facility and a $650.0 million term loan facility, both maturing on February 28, 2030.
• Acadia added 1,089 beds in 2025 through expansions of existing facilities (311 beds) and the opening of one wholly-owned facility and five joint venture facilities (778 beds), while closing five facilities totaling 382 beds.
• The company issued $550.0 million of 7.375% Senior Notes due 2033 on March 10, 2025, using the net proceeds to pay down outstanding borrowings under the Revolving Facility.
• Medicaid accounted for 57.7% of revenue in 2025, commercial payors 24.6%, Medicare 14.3%, and self-pay 2.0%.
• The Consolidated Total Net Leverage Ratio was 4.0x at December 31, 2025, in compliance with the Credit Facility covenant of not more than 5.0 to 1.0.
• Cash provided by operating activities increased slightly to $131.9 million in 2025 from $129.7 million in 2024, despite the decrease in earnings, due to non-cash charges and timing of legal settlement payments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the substantial net loss, significant goodwill impairment, and increased legal expenses, which overshadow the underlying revenue growth and strategic expansions.

Positives

• Revenue increased by 5.0% to $3,312.8 million for the year ended December 31, 2025, demonstrating continued business growth.
• Same facility revenue grew by 4.9%, driven by a 2.1% increase in patient days and a 2.8% increase in revenue per patient day, indicating organic growth and demand for services.
• The company expanded its operational footprint by adding 1,089 beds in 2025 through existing facility expansions, one wholly-owned facility, and five joint venture facilities, demonstrating execution of its growth strategy.
• New joint venture partnerships were established with reputable healthcare systems including Henry Ford Health, Geisinger Health, Ascension Seton, Fairview Health Services, and ECU Health.
• The company opened 15 Comprehensive Treatment Centers (CTCs) in 2025, expanding its care continuum for opioid use and other substance use disorders.
• A new Credit Facility was secured on February 28, 2025, providing $1.0 billion in revolving credit and a $650.0 million term loan, refinancing prior debt and providing capital for future growth.
• The company was in compliance with all financial covenants under its Credit Facility at December 31, 2025, with a Consolidated Total Net Leverage Ratio of 4.0x (below the 5.0x limit).
• Management believes the company is well-positioned to meet growing demand for behavioral healthcare services, leveraging its national footprint and experienced team.
• The company maintains a diversified revenue and payor base across 40 states and Puerto Rico, mitigating risk from any single facility or state.

Negatives

• Reported a significant net loss of $1,102.8 million for the year ended December 31, 2025, a substantial reversal from a net income of $255.6 million in 2024.
• Incurred a massive non-cash goodwill impairment charge of $996.2 million in 2025, reflecting a decrease in the fair value of its behavioral healthcare services reporting unit.
• Legal settlements expense increased significantly to $151.0 million in 2025, including a $147.5 million expense for the 2019 Securities Litigation.
• Other operating expenses increased to $553.3 million (16.7% of revenue) in 2025 from $440.8 million (14.0% of revenue) in 2024, partly due to unfavorable adjustments of $52.7 million to self-insured professional and general liability claims.
• Interest expense increased to $138.9 million in 2025 from $116.4 million in 2024, primarily due to increased borrowings.
• The company's stock price experienced a significant decline, falling from $78.85 at December 31, 2024, to $28.22 at December 31, 2025.
• Days sales outstanding (DSO) increased to 49 days at December 31, 2025, from 43 days at December 31, 2024, attributed to new facilities ramping up and identifiable payor delays.
• The expiration of enhanced ACA premium tax credits on December 31, 2025, is expected to lead to higher marketplace premiums and a significant reduction in enrollees for the 2026 plan year, potentially increasing uncompensated care.
• The One Big Beautiful Bill Act (OBBBA) reduces federal Medicaid expenditures and tightens eligibility requirements, which may negatively impact financial performance due to potential mid-year coverage loss and increased uncompensated care.
• Experienced significant turnover among executive officers, including the departure of the Chief Executive Officer in January 2026 and resignations of the Chief Financial Officer and Chief Operating Officer in August and November 2025, respectively.

Risks

• Governmental investigations, regulatory actions, and whistleblower lawsuits could result in repayment obligations, substantial monetary penalties, fines, corporate integrity agreements, exclusion from government health programs, and negative publicity.
• Legal proceedings based on negligence, medical malpractice, or unlawful detention from service users or employees could lead to substantial damage awards or settlements, as exemplified by the $400.0 million payment in the Desert Hills Litigation.
• Failure to comply with extensive laws and government regulations (e.g., Anti-Kickback Statute, Stark Law, False Claims Act, EKRA, HIPAA, EMTALA) could result in civil and criminal penalties, exclusion from government healthcare programs, and reputational harm.
• Increased inflationary pressure on personnel, construction, and supply chain costs may adversely impact profitability, and sustained inflation could lead to higher interest rates and limit growth strategy.
• The industry trend toward value-based purchasing and sole-source contracts by insurance companies and managed care organizations may negatively impact revenue and limit patient acquisition.
• An increase in uninsured or underinsured patients due to healthcare policy changes (e.g., OBBBA, expiration of ACA premium tax credits) or deterioration in accounts receivable collectability could harm results of operations.
• Patient incidents (e.g., deaths, sexual abuse, assaults, elopements) or failure to provide appropriate care could lead to increased regulatory burdens, governmental investigations, litigation, negative publicity, and adverse effects on stock price.
• Joint ventures may use significant resources, be unsuccessful, and expose the company to unforeseen liabilities, with potential delays in positive financial impact from de novo facilities.
• Business growth and acquisition strategies expose the company to integration risks, potential failure to realize expected benefits, assumption of unknown liabilities, and intense competition for acquisition candidates.
• Cybersecurity incidents, including ransomware attacks, hacking, and data breaches, could result in substantial sanctions, fines, damages, civil and criminal penalties, reputational harm, and increased costs.
• Concentrated operations in Pennsylvania, California, and Tennessee make the company sensitive to regulatory, economic, environmental, and competitive changes in those states.
• Natural disasters and climate change risks (e.g., hurricanes, wildfires, long-term adverse weather) could disrupt operations, cause property damage, and lead to outmigration from communities where facilities are located.
• Failure to cultivate new or maintain established relationships with physicians, managed care companies, and other referral sources could adversely affect patient volumes and revenue.
• Competition in the highly competitive healthcare industry from other behavioral healthcare providers, tax-supported agencies, non-profits, and local operators may lead to declines in patient volumes.
• Inability to extend leases at expiration or unfavorable lease terms could harm business, financial condition, or results of operations.
• Controls designed to reduce inpatient services (utilization review, preadmission authorization) by Medicare, Medicaid, and commercial payors may reduce revenue by shifting patients to lower levels of care.
• Dependence on key management personnel, including the Chief Executive Officer, and the failure to attract and retain them, or a significant portion of local facility management, could harm the business.
• Labor shortages, higher turnover rates, and competition for staffing may increase labor costs and reduce profitability, especially for nurses, qualified addiction counselors, and other medical support personnel.
• The company is a holding company and relies on its subsidiaries for funds, and liabilities of one subsidiary could be imposed on others.

Future Outlook

The company's strategy is to become the indispensable behavioral healthcare provider for high-acuity and complex-needs patient populations, focusing on five growth pathways: expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions, and expansion across its continuum of care. Management expects to leverage increased size and geographic scale for national marketing, increased out-of-state referrals, and a broader range of services. The company believes it has sufficient capital to fund requirements through the next 12 months and long-term, despite ongoing macroeconomic uncertainties and potential impacts from healthcare policy changes like the OBBBA and the expiration of ACA premium tax credits.

Management Comments

• "Our business strategy is to become the indispensable behavioral healthcare provider for the high-acuity and complex needs patient population."
• "We are committed to providing the communities we serve with high-quality, cost-effective behavioral healthcare services, while growing our business, increasing profitability and creating long-term value for our stockholders."
• "Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise."
• "Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume of out-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count through acquisitions, wholly-owned de novo facilities, joint ventures and bed additions in existing facilities."
• "We believe that we are well positioned to help meet the growing demand for behavioral healthcare services and recorded revenue growth of 5.0% for the year ended December 31, 2025 compared to the year ended December 31, 2024."
• "While we experienced higher wage inflation compared to historical averages in recent years, we continue to see stability in our labor costs and our proactive focus helps us manage through this environment."
• "We remain focused on ensuring that we have the level of staff to meet the demand in our markets across 40 states and Puerto Rico."
• "Management believes we continue to be well positioned for investments in our facilities, expansion into new and existing markets and enhancement of our capabilities and infrastructure."
• "Management believes our focus on behavioral healthcare and history of completing acquisitions provides us with a strategic advantage in sourcing, evaluating and closing acquisitions."
• "Although we cannot provide any assurance, we believe that we will have sufficient capital available to fund requirements through the 12 month period following the filing of this Annual Report on Form 10-K, and based on current expectations, the long term."

Industry Context

StockSavvy.ai notes that Acadia Healthcare operates within a behavioral healthcare industry experiencing significant demand growth due to increased awareness of mental health and substance abuse conditions. Legislative trends, such as the MHPAEA and SUPPORT Act, aim to increase access to services, which should generally benefit providers like Acadia. However, the industry is also highly fragmented and undergoing consolidation, leading to increased competition for acquisitions. The company's reliance on government payors (Medicaid, Medicare) exposes it to budgetary pressures and policy changes, such as the OBBBA, which could reduce reimbursement and tighten eligibility. The expiration of ACA premium tax credits also poses a risk of increased uninsured patients, a challenge for the broader healthcare sector. The company's focus on high-acuity and complex needs patients positions it in a segment with potentially higher reimbursement rates, but also higher operational and liability risks.

Comparison to Industry Standards

• Acadia Healthcare is the leading publicly traded pure-play provider of behavioral healthcare services in the U.S., suggesting a strong market position compared to diversified healthcare companies or smaller, regional players.
• The company's stock performance for the year ended December 31, 2025, showed a significant decline to $28.22 from $78.85, underperforming both the S&P 500 Index (which rose to $196.16 from $166.40) and the S&P Health Care Services Select Industry Index (which rose to $113.00 from $94.85). This indicates a substantial underperformance relative to broader market and industry benchmarks.
• The goodwill impairment charge of $996.2 million in 2025 is a significant event, reflecting a re-evaluation of asset values that may be more pronounced than typical industry adjustments, potentially signaling challenges in realizing expected returns from past acquisitions or operational units.
• The increase in legal settlements expense to $151.0 million, particularly the $147.5 million for the 2019 Securities Litigation, suggests a higher-than-average litigation burden compared to industry peers, which could impact investor confidence and operational focus.
• The increase in Days Sales Outstanding (DSO) to 49 days from 43 days indicates a potential weakening in accounts receivable management or challenges with payor timeliness, which could be a concern if it deviates significantly from industry best practices for collections.

Management Changes

Corporate Governance

Legal Proceedings

• Desert Hills Litigation: The company paid an aggregate of $400.0 million on January 19, 2024, to settle three lawsuits related to abuse by a foster parent at a subsidiary, with no admission of liability. A sixth similar lawsuit was filed on January 30, 2024, for which the ultimate liability cannot be reasonably estimated.
• 2019 Securities Litigation: A consolidated class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Exchange Act. The parties entered into a settlement stipulation on November 24, 2025, for $179.0 million, with $147.5 million included in legal settlements expense and $31.5 million covered by insurance. Preliminary court approval was granted on January 15, 2026.
• Kachrodia v. Acadia Healthcare Company, Inc., et al.: A consolidated class action complaint filed on July 10, 2025, alleging violations of Sections 10(b) and 20(a) of the Exchange Act. A motion to dismiss was fully briefed as of December 22, 2025, with no ruling yet. The ultimate liability cannot be reasonably estimated.
• Derivative Actions: Multiple derivative actions (Davydov v. Jacobs, et al., Beard v. Jacobs, et al., Pfenning v. Jacobs, et al., Solak v. Jacobs, et al., Kachrodia v. Osteen, et al.) have been filed against former and current officers and directors. The parties to several of these cases are in active negotiation of a settlement, and the company does not expect to incur a material loss.
• Government Investigation (W.D.Mo. and SEC): The company received grand jury subpoenas from the U.S. District Court for the Western District of Missouri (DOJ Criminal Division) in September 2024 (re-issued December 2024) related to its acute care service line, admissions, length of stay, and billing practices. The SEC also issued subpoenas for similar information and related to the CTC service line. The company is cooperating with authorities and conducting an internal investigation, but cannot reasonably estimate the ultimate liability.

Stakeholder Impact

• Shareholders: Experienced a significant decline in stock price and a substantial net loss, impacting investment value. The share repurchase program could offer some support, but the overall financial performance is a major concern.
• Employees: Faced rising labor costs and turnover, leading to the use of more expensive contract labor. The company's commitment to being an employer of choice and offering comprehensive benefits aims to mitigate these issues. Management changes at the executive level could create uncertainty.
• Patients/Clients: The company's growth strategy aims to provide high-quality, cost-effective behavioral healthcare services and expand access. However, potential mid-year loss of Medicaid coverage due to OBBBA and increased uninsured/underinsured patients from ACA changes could disrupt treatment continuity and access to care.
• Payors (Government and Commercial): Government payors are under budgetary pressures, leading to potential payment reductions and tighter eligibility requirements (OBBBA). Commercial payors are aggressively managing reimbursement levels, impacting the company's revenue.
• Creditors: The company refinanced its credit facility and issued new senior notes, demonstrating access to capital. Compliance with debt covenants is maintained, but the overall financial loss and increased debt levels warrant close monitoring.

Next Steps

• Continue to drive organic growth of existing facilities by providing a broader range of services and increasing bed counts.
• Fuel facility growth through accelerated joint venture partnerships and de novo builds, and pursue programmatic mergers and acquisitions.
• Accelerate expansion across the care continuum, particularly for patients with opioid use and other substance use disorders.
• Actively manage capital structure and opportunistically engage in financing transactions to strengthen the long-term financial profile.
• Monitor and comply with new and evolving healthcare legislation and regulations, including the OBBBA and HIPAA security regulations.
• Address payor delays and accelerate collections to improve Days Sales Outstanding (DSO).
• Actively recruit new executive officers to fill recent vacancies and integrate them into the business.
• Continue to evolve the cybersecurity program to address emerging threats and risks.

Key Dates

Recommendation

The company reported a substantial net loss of over $1.1 billion for 2025, primarily due to a nearly $1 billion goodwill impairment charge and significant legal settlement expenses. While revenue growth and strategic expansions are positive, the magnitude of the loss, the underperformance of the stock relative to market and industry indices, and ongoing legal and regulatory uncertainties, including potential impacts from changes in government healthcare programs, indicate significant financial headwinds and increased risk. The executive turnover further adds to operational uncertainty. A seasoned investor would likely view these factors as strong indicators to sell or avoid the stock until there is clear evidence of financial stabilization and resolution of major liabilities.

Keywords

Behavioral Healthcare, Mental Health, Substance Abuse Treatment, SEC Filing, 10-K, Financial Results, Net Loss, Goodwill Impairment, Legal Settlements, Credit Facility, Debt, Joint Ventures, Facility Expansion, Medicaid, Medicare, Cybersecurity, Risk Factors, Corporate Governance, Executive Turnover, Healthcare Regulation